{
  "id": "CD015219.PUB2",
  "draft": "Is favipiravir (an antiviral drug) effective for treating COVID-19?\n\nKey Messages\n- We are unsure if favipiravir works for COVID-19 because the evidence we have is not strong enough, and it may cause more unwanted or harmful effects.\n- Researchers found that favipiravir may not make a difference in whether people need to go to the hospital, need oxygen therapy, or recover from COVID-19.\n- We need more research to understand the benefits and harms of using favipiravir to treat COVID-19 and to get high-quality evidence to inform decisions.\n\nWhat is COVID-19 and why is it a problem?\nCOVID-19 is a disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (a type of virus). It has been challenging healthcare systems and societies worldwide since its outbreak. COVID-19 can lead to severe respiratory problems, and its impact has been felt globally. Common treatments for COVID-19 include supportive care, such as rest, hydration, and oxygen therapy, as well as experimental antiviral treatments.\n\nWhat is favipiravir and how is it used in treating COVID-19?\nSome experts have suggested the antiviral drug favipiravir as a potential treatment for COVID-19. Researchers have evaluated it in several randomized controlled trials (RCTs) (a type of scientific study) to assess its effectiveness in treating people with COVID-19. People usually take a high dose on the first day, followed by a lower dose for several days. However, it is still unclear whether favipiravir has a definite role in treating COVID-19.\n\nWhat did the review authors want to find out?\nWe wanted to see how well favipiravir worked for people with COVID-19 compared to no treatment, standard care, or other antiviral drugs. We wanted to find out if favipiravir, compared to other treatments, could:\n- reduce the risk of death;\n- prevent people from needing to go to the hospital;\n- stop the illness from getting worse and requiring a breathing machine (mechanical ventilation);\n- help people get better faster.\n\nWhat methods did we use?\nWe searched for studies comparing favipiravir to other treatments for COVID-19, summarized their results, and rated our confidence in the evidence.\n\nWhat did we find?\nWe found 25 studies that involved 5750 adults with COVID-19. Most participants were hospitalized with mild to moderate disease (89%) and were under 60 years of age. The studies were conducted in 13 countries including Bahrain, Brazil, China, India, Iran, Kuwait, Malaysia, Mexico, Russia, Saudi Arabia, Thailand, the UK, and the USA. Most studies compared favipiravir to a placebo (a dummy treatment) or the usual standard of care. A few studies compared it to other antiviral drugs. Treatment usually started with a high dose on the first day, followed by lower doses for one to two weeks.\n\nWhat are the main results of favipiravir for COVID-19?\nFavipiravir may make little to no difference in the need for admission to hospital, the progression to oxygen therapy, or the time to clinical improvement for people with COVID-19. However, it may cause more adverse events overall. We are not sure if favipiravir reduces the risk of dying from any cause, needing a breathing machine, or having other serious harmful effects.\n\nWhat are the limitations of the evidence?\nThe evidence is limited because the studies were very small, participants may have known which treatment they received (lack of blinding), and not all studies reported data on all outcomes of interest.\n\nIs the evidence up to date?\nThe evidence is up to date to July 2023.\n\nFuture research should explore the benefits and harms of using favipiravir to treat COVID-19. We need high-quality evidence to help people make informed decisions.",
  "metrics": [
    {
      "linguistic_evaluation": {
        "words": {
          "value": 619,
          "rating": "within_limit",
          "direction": null,
          "feedback": null
        },
        "sentences": {
          "value": 34,
          "rating": "info",
          "direction": null,
          "feedback": null
        },
        "words_per_sentence": {
          "value": 18.205882352941178,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "passive_voice": {
          "value": 16,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "active_voice": {
          "value": 66,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "pronouns": {
          "value": 33,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "nominalization": {
          "value": 19,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "nouns": {
          "value": 146,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "flesch_reading_ease": {
          "value": 57.014187731635474,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "flesch_kincaid_grade": {
          "value": 9.829841775159178,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "automated_readability_index": {
          "value": 9.176107573885773,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "coleman_liau_index": {
          "value": 9.418869143780292,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "gunning_fog_index": {
          "value": 14.002869904019768,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "lix": {
          "value": 45.99263518008173,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "rix": {
          "value": 5.0588235294117645,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "smog_index": {
          "value": 13.535653752852738,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "dale_chall_readability": {
          "value": 6.719037612848048,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "complex_words_dc": {
          "value": 228,
          "rating": "P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 228.0 to <160.0 (median)"
        },
        "complex_words": {
          "value": 104,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "long_words": {
          "value": 172,
          "rating": "P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 172.0 to <122.0 (median)"
        }
      },
      "word_count_status": {
        "word_count": 619,
        "limit": 850,
        "status": "within_limit",
        "message": "Word count: 619 ✓ WITHIN LIMIT (≤850 words)"
      },
      "summary": {
        "P25_count": 8,
        "P50_count": 0,
        "P75_count": 8,
        "P90_count": 2,
        "P10_count": 0,
        "BEYOND_P90_count": 0,
        "BELOW_P10_count": 0,
        "total_evaluated": 18,
        "P25_percentage": 44.44444444444444,
        "P50_percentage": 0,
        "P75_percentage": 44.44444444444444,
        "P90_percentage": 11.11111111111111,
        "P10_percentage": 0,
        "BEYOND_P90_percentage": 0,
        "BELOW_P10_percentage": 0,
        "best_quartile_rate": 88.88888888888889,
        "overall_assessment": "HIGHLY CONFORMS TO TYPICAL PLS PATTERNS"
      }
    }
  ],
  "evaluation": [
    {
      "grade": "NOT_APPROVED",
      "feedback": "This is a strong draft that meets all critical requirements for accuracy and structure. However, it is not approved because several key opportunities to improve clarity for a lay audience have been missed. The feedback below focuses on simplifying complex terms and explaining research concepts more clearly to ensure the summary is as accessible as possible for patients and the public.\n\nHere are the top 3 improvements needed:\n\n1.  **Simplify the definition of COVID-19.** The initial explanation uses a very long, technical name for the virus which can be intimidating for readers.\n    *   **Problematic text:** \"COVID-19 is a disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (a type of virus).\"\n    *   **Suggested rewrite:** \"COVID-19 is an illness caused by a virus called SARS-CoV-2.\"\n\n2.  **Replace medical jargon with plain language consistently.** The term \"adverse events\" is well-defined in the key messages but then used without explanation in the main results, which could confuse readers who skip to that section.\n    *   **Problematic text:** \"However, it may cause more adverse events overall.\"\n    *   **Suggested rewrite:** \"However, it may cause more unwanted or harmful effects overall.\"\n\n3.  **Clearly explain research-specific terms.** The limitations section introduces the concept of \"blinding\" but the explanation could be more direct and easier to understand.\n    *   **Problematic text:** \"...participants may have known which treatment they received (lack of blinding)...\"\n    *   **Suggested rewrite:** \"...in some studies, people knew which treatment they were getting. This can affect the results.\"\n",
      "pls_evaluation_summary": "The linguistic analysis shows the draft highly conforms to typical PLS patterns, with 89% of features falling in the best quartile for readability and structure. However, the analysis also flags two metrics in the P90 range: 'complex_words_dc' (Dale-Chall unfamiliar words) and 'long_words'. This statistical finding supports the editorial feedback, indicating that the primary area for improvement is simplifying specific vocabulary and technical terms to enhance reader understanding."
    }
  ]
}